Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

“Multiple myeloma is the second most common blood ... We also use small molecules that can be, for example, blockers of certain pathways or certain functions in the cells,” Dr. Landgren ...

When experienced researcher Renato Aguilera happened across the chemical structure of a tried-and-true antimalarial drug one ...

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial.

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti. BCMA-directed cell therapy ...

Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer therapy.

A 63-year-old patient with multiple myeloma developed T cell lymphoma in the blood ... analyzed the transcriptome of the CAR-T cells to investigate genes and signalling pathways. These methods had ...